Gunnar Folprecht,¹ Shubham Pant,² Joon Oh Park,³ Wu-Chou Su,⁴ Martin Schuler,⁵ Yohann Loriot,⁶ Gopa lyer,^{7,8} Toshihiko Doi,⁹ Shukui Qin,¹⁰ Josep Tabernero,¹¹ Hans Prenen,¹² Helen Winter,¹³ Graziela Z. Dal Molin,¹⁴ Hussein Sweiti,¹⁵ Saltanat Najmi,¹⁵ Constance Hammond,¹⁵ Huimin Liao,¹⁶ Shibu Thomas,¹⁵ Spyros Triantos,¹⁵ Yin-Hsun Feng¹⁷

¹Technical University Dresden, Medical Faculty Carl Gustav Carus, Medical Dept. I, Dresden, Germany; ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ⁴Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; ⁵Department of Medical Oncology, West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany; ⁶Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ⁷Genitounnary Oncology, Memonal Sloan Kettenng Cancer Center, New York, NY, USA; ⁸Weil Cornell Medical College New York, NY, USA; ⁹National Cancer Center Hospital East, Kashiwa, Japan; ¹⁰The People's Liberation Army 81 Hospital, Nanjing, China; ¹¹Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; ¹²University Hospital Antwerp, Edegem, Belgium; ¹³Bristol Haematology and Oncology Centre, Bristol, UK; ¹⁴Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil; ¹⁵Janssen Research & Development, LLC, Spring House, PA, USA; ¹⁶Statistics & decision sciences, Janssen China R & D Center, Shanghai, China; ¹⁷Division of Hematology and Oncology, Chi-Mei Medical Center, Tainan, Taiwan

Originally Presented by: S Pant at the 2024 ASCO Annual Meeting; May 31 – June 4, 2024; Chicago, IL, USA

https://www.congresshub.com/Oncology/D GHO2024/Erdafitinib/Folprecht

Scan the QR code

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

KEY TAKEAWAY



Data from a pooled analysis of the RAGNAR and LUC2001 studies confirm robust efficacy of erdafitinib in a diverse population of patients with advanced or metastatic CCA and prespecified *FGFR* fusions or mutations



CCA, cholangiocarcinoma; FGFR, fibroblast growth factor receptor

Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

CONCLUSIONS



Erdafitinib demonstrated a high ORR (55.1%), DCR (98.7%) and durable responses (mDOR: 6.9 months) per IRC in patients with advanced or metastatic CCA harboring susceptible *FGFR* alterations

Safety data were consistent with the known safety profile of erdafitinib

CCA, cholangiocarcinoma; DCR, disease control rate; FGFR, fibroblast growth factor receptor; IRC, Independent Review Committee; mDOR, median duration of response; ORR, objective response rate



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

INTRODUCTION

- Patients with advanced CCA have a median survival of <12 months and 5-year survival rates of ≤10%^{1,2}
- Up to 15% of patients with CCA harbor *FGFR* gene aberrations, and selective FGFR inhibitors have been shown to improve outcomes in *FGFR*-altered CCA³
- Erdafitinib is an oral selective pan-FGFR inhibitor approved in the US for the treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations who have progressed on or after ≥1 line of prior systemic therapy⁴
 - Primary analyses from the RAGNAR (in various solid tumors) and LUC2001 studies have shown efficacy and manageable safety of erdafitinib in patients with advanced CCA and FGFR alterations^{5,6}
- Here we report a pooled analysis of patients with CCA treated in the RAGNAR and LUC2001 studies

1. Ramírez-Merino N, et al. *World J Gastrointest Oncol.* 2013;5:171-176. 2. Yu TH, et al. *Sci Rep.* 2021;11:3990. 3. Goyal L, et al. *Cancer Treat Rev.* 2021;95:102170. 4. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. 2024; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma. 5. Pant S, et al. *Lancet Oncol.* 2023;24:925-935. 6. Feng YH, et al. Poster #430 presented at the ASCO Gastrointestinal Cancers Symposium 2022; San Francisco, CA, USA. CCA, cholangiocarcinoma; *FGFR*, fibroblast growth factor receptor; US, United States



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

METHODS

RAGNAR study design (NCT04083976)¹

- A single-arm, multicenter, phase 2 study in 15 countries
- Patients: ages ≥12 years with advanced or metastatic tumors of any histology (except urothelial cancer) with predefined FGFR1-4 alterations and disease progression on ≥1 previous line of systemic therapy, who exhausted all standard therapies
 - Treatment: erdafitinib 8 mg QD (with pharmacodynamically guided up-titration to 9 mg/day) on continuous 21-day cycles

LUC2001 study design (NCT02699606)

- An open-label, multicenter, phase 2a study in Asian patients (China, Taiwan, and South Korea)
- Patients: adults with advanced non-small cell lung cancer, urothelial cancer, esophageal cancer, or CCA with predefined FGFR1-4 alterations and disease progression on ≥1 prior line of systemic therapy
 - Treatment: erdafitinib 8 mg QD (with pharmacodynamically guided up-titration to 9 mg/day) on 28-day treatment cycles

1. Pant S, et al. *Lancet Oncol*. 2023;24:925-935 CCA, cholangiocarcinoma; *FGFR*, fibroblast growth factor receptor; QD, once daily



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

METHODS

Outcomes

- Efficacy
 - objective response rate (ORR, complete response [CR] + partial response [PR]) per RECIST 1.1 criteria by an Independent Review Committee (IRC)
 - duration of response (DOR)
 - disease control rate (DCR; i.e., CR+PR+stable disease [SD])
 - progression free survival (PFS)
 - overall survival (OS)
- Safety: treatment-emergent adverse events (TEAEs)



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

Baseline demographics (treated patients)

- At data cutoff (RAGNAR: December 4, 2023; LUC2001: November 19, 2021)
 - 78 patients with CCA received erdafitinib (RAGNAR: n=66; LUC2001: n=12)
 - Median efficacy follow-up was 14.7 months
- Patients had a median age of 56 years;
 60.3% were female; 47.4% were white, and
 38.5% were Asian

	.9	
Characteristics	N=78	
Age, median (range), years	56.0 (24; 77)	
Sex, women, n (%)	47 (60.3)	
Race, n (%)		
White	37 (47.4)	
Asian	30 (38.5)	
Black or African American	2 (2.6)	
Native Hawaiian or other Pacific Islander	1 (1.3)	
Not Reported	8 (10.3)	



CCA, cholangiocarcinoma

Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

Baseline disease characteristics (treated patients)

- Patients had a median of 2 prior lines of therapy; 92.0% patients had visceral metastases, and 16.7% of patients responded to their last line of therapy
- Overall, 93.6% of patients had *FGFR2* alterations, and 91.0% had *FGFR* fusions
- The most frequently co-altered genes among CCA patients (n=31) assessed for FGFR co-alterations in RAGNAR were BAP1 (19%), CDKN2A, CDKN2B (13% each), PIK3CA (10%), MTAP (6%), and TP53 (3%)

	$\sim 0^{\circ}$	
Characteristics	N=78	
ECOG performance status, n (%)		
0	34 (43.6)	
1	44 (56.4)	
Visceral metastases, n (%)ª	69 (92.0)	
Time from progression/relapse on the last line of treatment to I st dose, median (range), months ^b	0.95 (0.1-67.1)	
Number of prior lines of anti-cancer therapies, n (%)		
Median (range)	2.0 (1.0; 6.0)	
1	31 (39.7)	
2	33 (42.3)	
≥3	14 (17.9)	
Prior systemic therapy in advanced/metastatic setting, n (%)		
Chemotherapy	78 (100)	
Immunotherapy	11 (14.1)	
Other systemic therapy	69 (88.5)	
Best response to last line of prior systemic therapy		
ORR, n (%) [95% Cl]	13 (16.7) [9.2-26.8]	
FGFR altered gene, n (%)		
FGFR2	73 (93.6)	
FGFR3	5 (6.4)	
FGFR alteration type, n (%)		
Fusion	71 (91.0)	
Mutation	7 (9.0)	

an=75, applicable only to patients with metastatic disease; bn=75, applicable only to patients with non missing values for progression/relapse date of last line of treatment. CCA, cholangiocarcinoma; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; *FGFR*, fibroblast growth factor receptor; ORR, objective response rate




Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

Efficacy outcomes (treated patients)

- ORR per IRC was 55.1% (95% CI, 43.4–66.4), and the DCR was 98.7% (95% CI, 93.1–100; Figure 1)
- The median time to response was 1.7 months (range, 1.4–2.8), and the median DOR was 6.9 months (95% CI, 4.37–8.61) per IRC
- The clinical benefit rate (CR+PR+SD ≥4 months) per IRC was 70.5% (95% CI, 59.1–80.3)
- The median PFS was 8.5 (95% CI, 6.83–9.72) months, and the median OS was 18.1 (95% CI, 13.40–24.28) months



CI, confidence interval; CR; complete response; DCR, disease control rate; DOR, duration of response; IRC, Independent Review Committee; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease




Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

% reduction from baseline ORR, n (%), Median DOR [95% CI] (95% CI), months 41 (56.2) FGFR2 alteration 6.93 (4.37-8.28) [44.1-67.8] (n=73) FGFR3 alteration 2 (40.0) NE (2.83-NE) (n=5) [5.3-85.3 Maximal FGFR mutation 2 (28.6) NE (2.76-NE) (3.7 - 71.0)(n=7) FGFR fusion 41 (57.7) 6.93 (4.37-8.28) (45.4 - 69.4)(n=71)

Efficacy by *FGFR* alterations (treated patients)



- Responses were observed in patients with altered *FGFR2* and *FGFR3* genes and across both *FGFR* mutations and fusions
- Objective response to erdafitinib in patients with *FGFR* co-alterations was similar to those without co-alterations (data not shown)

Cl, confidence interval; CR, complete response; DOR, duration of response; *FGFR*, fibroblast growth factor receptor; IRC, Independent Review Committee; NE, non-estimable, ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

Safety summary

- Cr		
TEAEs, n (%)	N=78	
Any TEAEs	78 (100)	
Grade ≥3 TEAEs	50 (64.1)	
Serious TEAEs	12 (15.4)	
TEAEs leading to dose reduction	65 (83.3)	
TEAEs leading to dose interruption	64 (82.1)	
TEAEs leading to treatment discontinuation	6 (7.7)	
TEAEs leading to death	0	
XC X		

Data are n (%). Adverse events are coded using MedDRA Version 24.1. Patients were counted only once for any given event, regardless of the number of times they actually experienced the event. TEAEs, treatment-emergent adverse events



ѷ Originally Presented by: S Pant at the 2024 ASCO Annual Meeting; May 31 – June 4, 2024; Chicago, IL, USA

Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

RESULTS

TEAEs

 The most common drug-related TEAEs were hyperphosphatemia (82.1%), stomatitis (69.2%), palmar-plantar erythrodysesthesia (51.3%), diarrhea (50.0%), and dry mouth (48.7%)

2.	
N=78	
Any grade	Grade ≥3
64 (82.1)	4 (5.1)
54 (69.2)	14 (17.9)
40 (51.3)	5 (6.4)
39 (50.0)	2 (2.6)
38 (48.7)	2 (2.6)
25 (32.1)	0
25 (32.1)	2 (2.6)
21 (26.9)	7 (9.0)
19 (24.4)	1 (1.3)
18 (23.1)	1 (1.3)
18 (23.1)	0
17 (21.8)	4 (5.1)
17 (21.8)	0
17 (21.8)	0
16 (20.5)	3 (3.8)
	Any grade 64 (82.1) 54 (69.2) 40 (51.3) 39 (50.0) 38 (48.7) 25 (32.1) 25 (32.1) 21 (26.9) 19 (24.4) 18 (23.1) 17 (21.8) 17 (21.8) 17 (21.8)

Data are n (%). Adverse events are coded using MedDRA Version 24.1. Patients were counted only once for any given event, regardless of the number of times they actually experienced the event. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TEAEs, treatment-emergent adverse events



Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng

APPENDIX

REFERENCES:

- 1. Ramírez-Merino N, et al. World J Gastrointest Oncol. 2013;5:171-176.
- 2. Yu TH, et al. Sci Rep. 2021;11:3990.
- 3. Goyal L, et al. Cancer Treat Rev. 2021;95:102170.
- 4. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. 2024; <u>https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma</u>.
- 5. Pant S, et al. Lancet Oncol. 2023;24:925-935.
- 6. Feng YH, et al. Poster #430 presented at the ASCO Gastrointestinal Cancers Symposium 2022; San Francisco, CA, USA.

ACKNOWLEDGMENTS:

Erdafitinib (JNJ-42756493) was discovered in collaboration with Astex Pharmaceuticals.

Priya Ganpathy, MPH, CMPP (SIRO Clinpharm UK Limited) provided medical writing assistance and Jennifer Han, MS (Janssen Global Services) provided additional editorial support. Sandeep Chavan (SIRO Clinpharm Pvt. Ltd. India) provide graphic designing support.

FUNDING: This study was funded by Janssen Research & Development.

https://www.congresshub.com/Oncology/D GHO2024/Erdafitinib/Folprecht

Scan the QR code The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

